Synchron, a rival of Musk’s Neuralink rival, starts trials of its implant in the US
The wearer of the device will be able to conduct chores by thinking
Patients with paralysis can now control digital devices simply by thinking
As part of the trial, a paperclip-sized device will be implanted in six participants
Synchron is progressing faster than its industry rival, Elon Musk's Neuralink
Synchron, Elon Musk’s Neuralink rival, has begun human trials of its brain implant, which allows the wearer to control a computer solely through thinking.
The stentrode brain implant, which is roughly the size of a paperclip, will be installed in six patients with severe paralysis in New York and Pittsburgh.
Stentrode will allow patients to control digital devices simply by thinking, restoring their ability to conduct everyday chores like texting, emailing and online shopping. This is the first time the implant will be tested in the United States.
Synchron looks to be progressing faster than its main opponent, Neuralink, which is owned by Elon Musk. Synchron’s clinical trial, dubbed Command, is being overtaken under the US Food and Drug Administration’s first investigational device exemption.
Stentrode, Synchron’s product, is a brain-computer interface (BCI) that is implanted into the motor cortex of the brain via the jugular vein in a ‘minimally invasive operation.’ The system is intended for patients who are paralysed as a result of a variety of diseases, and it is intended to be user-friendly and dependable.
